International studies published last week linked a very widely used synthetic insulin to increased risk of cancer. But millions of Indian diabetes patients who use the drug have reason to be relieved after the US Food and Drug Administration (FDA) — and other regulatory authorities across the world — have decided to review the safety of the drug but have urged patients not to stop treatment.
In a statement earlier this week, the FDA restrained from giving the drug a clean chit but allayed fears.
“(The agency) is not concluding that there is no causal relationship between the drug product and emerging safety issue. Nor does it mean that FDA is advising health care professionals to discontinue prescribing the product,” the FDA said. It is investigating the case.
India has a 45-million diabetic population and is considered to be the global epicentre of the disease. Insulin glargine is approved to control blood glucose in patients with Type 1 and Type 2 diabetes. According to doctors in India, the drug is used by at least 30 per cent of patients with Type I diabetes and by about 70 per cent with Type II.
Its obviously a serious concern among the diabetic population of India. But as the FDA is reviewing the drug and has assured that immediate discontinuation is not needed, it can be well predicted, that the drug may not be so much dangerous as the rumor might say.
Apart from that we also want that our Indian researchers also do something to it, and why we will depend upon FDA only to tell whether it is safe to take the drug or not? We know how the people would be concerned hearing to this news, but from our part we can assure you, that as soon as we get some update from the FDA or any other reliable source about the matter we will alarm you.
Source: Indian Express.com